Ventures News

05/30/2019

Catapult, Prevent Biometrics Partner to Sync Safety, Performance Data

In conducting extensive trials with college and high school sports teams, Prevent Biometrics found value in syncing the impact data gleaned from its smart mouthguards with game video to provide context on collisions.


05/07/2019

Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test

Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer.


04/23/2019

Cleveland Clinic spinoff company to start clinical trials for Alzheimer's disease

Cleveland Clinic spinoff company NeuroTherapia Inc. will start clinical trials of a new drug targeting inflammation of the brain that's found in Alzheimer's and other neurological diseases, according to a news release.


04/04/2019

Shivom Partners With Cleveland Clinic Spinout Family Care Path

Shivom announced today that it has signed an agreement to offer Family Care Path's MyLegacy web-based clinical decision support application to its customers.


01/30/2019

GCV Rising Stars Awards 2019: Jack Miner

Jack Miner leads Cleveland Clinic Ventures, a team of venture experts charged with funding the full lifecycle – from product-development company to exit – at the US-based healthcare services provider.


01/02/2019

Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas

Developed through research at Cleveland Clinic, Juventas Therapeutics, the clinical stage biotechnology company, is a pioneer in non-viral gene therapies. Licensed and spun-out through Cleveland Clinic Innovations, Juventas raised more than $50 million to advance its primary gene therapy candidate JVS-100, from concept through Phase II clinical studies in heart failure and Peripheral Artery Disease (PAD).


12/12/2018

Subscribe From Subaru Ascent to Apple Watch Series 4: The biggest product launches of 2018

This year, American consumer confidence hit a near 18-year high. These conditions – which often translate to increased consumer spending – provide an ideal environment for companies to introduce innovative new products. Prevent Biometrics is listed at #5.


10/22/2018

Prevent BiometricsĀ® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring

Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.


06/01/2018

Cleveland Clinic spinoff develops mouthguard that accesses concussion effects

The atmosphere inside the boxing gym was humid and reeked of sweat. Antonio Nieves, a former Cleveland Golden Gloves champion bantamweight, adjusted his digital mouthguard as he waited for his sparring match to start.


05/29/2018

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”


   < 1 - 2 - 3 - 4  >   

Get In Touch With Us